Sequoia Sciences is part of the American Society of Pharmacognosy conference July 29 to August 2, 2017 in Portland, Oregon. Scientists Mark O'Neil Johnson and Russell Williams will present.
"Many of my patients with multidrug-resistant recurrent urinary tract infections have tried multiple antibiotics for years without success," said Liz D'Antonio, CRNP, director of clinical research, Anne Arundel Urology. " A vaccine presents a new approach that could offer new hope for these patients. We eagerly await the results of the next studies as it hopefully moves toward approval."
"While the search for new antibiotics continues, several studies have highlighted that vaccines also have benefits against AMR. By reducing cases of disease, they slow the rise of drug-resistant pathogens, because the microbes have fewer opportunities to multiply and evolve."
Upcoming "Interface of Science and Technology as Applied to Natural Product Research" conference will take place in Cancun, Mexico and feature particpants from around the globe.
Sequoia scientists recently published a paper describing the discovery of bifidenone, the lead compound for Sequoia's anticancer compound SQ1274.